ArticleEJNMMI reports2026

177Lutetium-PSMA-I&T therapy for metastatic castration-resistant prostate cancer (mCRPC): the first multicenter real-world study of 177Lu-PSMA-I&T in Brazil.

Helena F Bruzzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.